Literature DB >> 11017796

Human p32: a coactivator for Epstein-Barr virus nuclear antigen-1-mediated transcriptional activation and possible role in viral latent cycle DNA replication.

S Van Scoy1, I Watakabe, A R Krainer, J Hearing.   

Abstract

The Epstein-Barr virus (EBV) nuclear antigen-1 (EBNA-1) is required for the maintenance of the viral chromosome in latently infected, proliferating cells and plays a role in latent cycle DNA replication. EBNA-1 also functions as a positive and negative regulator of EBV gene expression. We have investigated the interaction of EBNA-1 with p32, a host mitochondrial protein that associates with EBNA-1 in EBV-positive Burkitt's lymphoma cells. Using a chromatin immunoprecipitation assay, we found that a fraction of p32 localizes to the viral latent cycle origin of DNA replication oriP in vivo. p32 binds EBNA-1 independently of other proteins or DNA. EBNA-1 variants lacking one of two p32 binding elements did not interact stably with p32 in cultured cells and were defective for both transcriptional activation of a reporter gene linked to oriP FR and replication and/or maintenance of a plasmid bearing oriP. These results support a role for p32 in transcriptional activation by EBNA-1 and suggest that p32 plays a role in EBV latent cycle DNA replication. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11017796     DOI: 10.1006/viro.2000.0508

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  The trypanosome homolog of human p32 interacts with RBP16 and stimulates its gRNA binding activity.

Authors:  M L Hayman; M M Miller; D M Chandler; C C Goulah; L K Read
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

2.  Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1.

Authors:  Hong Wu; Priya Kapoor; Lori Frappier
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

3.  The replicator of the Epstein-Barr virus latent cycle origin of DNA replication, oriP, is composed of multiple functional elements.

Authors:  M D Koons; S Van Scoy; J Hearing
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

4.  The Herpesvirus Saimiri open reading frame 73 gene product interacts with the cellular protein p32.

Authors:  Kersten T Hall; Mathew S Giles; Michael A Calderwood; Delyth J Goodwin; David A Matthews; Adrian Whitehouse
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Cellular splicing and transcription regulatory protein p32 represses adenovirus major late transcription and causes hyperphosphorylation of RNA polymerase II.

Authors:  Christina Ohrmalm; Göran Akusjärvi
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

6.  Role for G-quadruplex RNA binding by Epstein-Barr virus nuclear antigen 1 in DNA replication and metaphase chromosome attachment.

Authors:  Julie Norseen; F Brad Johnson; Paul M Lieberman
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

7.  Identification of human cytomegalovirus UL84 virus- and cell-encoded binding partners by using proteomics analysis.

Authors:  Yang Gao; Kelly Colletti; Gregory S Pari
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

8.  Mitotic chromosome interactions of Epstein-Barr nuclear antigen 1 (EBNA1) and human EBNA1-binding protein 2 (EBP2).

Authors:  Vipra Kapur Nayyar; Kathy Shire; Lori Frappier
Journal:  J Cell Sci       Date:  2009-11-03       Impact factor: 5.285

9.  The Ustilago maydis a2 mating-type locus genes lga2 and rga2 compromise pathogenicity in the absence of the mitochondrial p32 family protein Mrb1.

Authors:  Miriam Bortfeld; Kathrin Auffarth; Regine Kahmann; Christoph W Basse
Journal:  Plant Cell       Date:  2004-07-23       Impact factor: 11.277

10.  EBNA1-mediated recruitment of a histone H2B deubiquitylating complex to the Epstein-Barr virus latent origin of DNA replication.

Authors:  Feroz Sarkari; Teresa Sanchez-Alcaraz; Shan Wang; Melissa N Holowaty; Yi Sheng; Lori Frappier
Journal:  PLoS Pathog       Date:  2009-10-16       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.